ClinicalTrials.gg
Status unknownNCT05405504Updated Jun 14, 2022

Evaluation of ReDS Pro System V2.7 and ReDS ICU in Patients With Heart Failure

An observational study in Heart Failure, sponsored by Christian Hassager. Status unknown at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-14.

Sponsored by Christian Hassager · Observational

How we know

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.

Planned enrollment
51st of 54
25 · median 213
Started
2022
with 12 others
Observational
54 of 242
19 open now
Registered
182nd of 242
by date

Among the 242 studies in Heart Failure with a site in Denmark, this one is the 51st largest by planned enrollment of the 54 observational ones that give a count, is one of 13 that started in 2022, is one of 54 observational ones, and was the 182nd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 242 studies in Heart Failure with a site in Denmark, or all of them as a file.
02

Study summary

The study is an investigator-initiated, prospective cohort trial. The trial aims to evaluate ReDS Pro System V2.7 and ReDS ICU in patients with heart failure (HF).

Read the detailed description

The study is an investigator-initiated, prospective cohort trial. The trial aims to evaluate ReDS Pro System V2.7 and ReDS ICU in patients with heart failure (HF). The overall purposes are:

  • to evaluate the ReDS efficacy measurements of lung fluid compared to pulmonary artery pressure guided therapy with CardioMEMS in out-patients with HF.
  • to describe the feasibility of ReDS ICU in patients admitted to an ICU with HF

For the out-patient part, the patients will be recruited from the outpatient clinic at Rigshospitalet. The patient must be at least 18 years, have a history of chronic HF, and already monitored using CardioMEMS and must not fulfill any of the exclusion criteria.

For the ICU part, the patients will be recruited at the ICU department at the Heart Center at Rigshospitalet. The patient must be at least 18 years, intubated, and unconscious or sedated (Glasgow Coma Score \<8), and already monitored using Swan-Ganz and arterial catherization and must not fulfill any of the exclusion criteria.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

ICU part:

Acute heart failure patients with Swan-Ganz catheter and an arterial catheter.

Outpatient part:

Chronic heart failure patients with CardioMEMS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

ICU part:

  • at least 18 years of age
  • hospitalized in ICU setting at Rigshospitalet
  • intubated
  • unconscious or sedated (Glasgow Coma Score \<8)
  • monitored using Swan-Ganz and arterial catherization.

Out-patient part:

  • at least 18 years of age
  • history of Chronic heart failure > 3 months
  • CardioMEMS

Exclusion criteria

Exclusion Criteria:

ICU part:

  • pacemaker or ICD on the right side
  • congenital heart malformations or intra-thoracic mass that would affect the right lung anatomy (e.g. dextrocardia, lung carcinoma)
  • wounds, burns, healing tissue, skin infection or recent skin graft or flap where the sensors should be attached to the skin
  • habitus is out of range due to one or more of the following
  • height less than 155 cm or higher than 195 cm
  • estimated of less than 22 or more than 36
  • standard active therapy has been stopped as the patient is inevitably dying.

Out-patient part:

  • pacemaker or ICD on the right side
  • congenital heart malformations or intra-thoracic mass that would affect the right lung anatomy (e.g. dextrocardia, lung carcinoma)
  • wounds, burns, healing tissue, skin infection or recent skin graft or flap where the sensors should be attached to the skin
  • habitus is out of range due to one or more of the following Height less than 155 cm or higher than 195 cm BMI of less than 22 or more than 38 For BMI 36 to 38, chest size ruler should be 39 or less
  • cancer or other severe non-cardiac disease with estimated less than 1 year
  • planned hospitalization for ICD, pacemaker, lung or heart surgery including heart transplantation during the study period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No

Groups and cohorts

  • ICU part

    Acute heart failure patients with Swan-Ganz catheter and an arterial catheter.

    Device: Remote Dielectric Sensing (ReDS)

  • Out-patient part

    Chronic heart failure patients with CardioMEMS.

    Device: Remote Dielectric Sensing (ReDS)

Interventions

  • DeviceRemote Dielectric Sensing (ReDS)

    Non-invasive device designed for the measurement of lung fluid using extremely low power electromagnetic waves. The ReDS Pro System V2.7 system has CE approval (3900874CE01) and FDA clearance.

06

What researchers measure

Primary outcomes

  1. Correlation between ReDS ICU fluid parameters and Swan-Ganz measurements

    Measurements on Swan-Ganz catheter (CVP, PAP, PCWP - all in mmHg) and the percentage of fluid in the lungs (%)

    Time frame: Daily Swan-Ganz catheter and ReDS ICU measurements the first 72 hours after Swan-Ganz implantation

  2. Correlation between ReDS v2.7 fluid parameters and CardioMEMS measurements

    mPAP (mmHg), dPAP (mmHg) and the percentage of fluid in the lungs (%)

    Time frame: 3 months

Secondary outcomes

  1. Changes in ReDS ICU fluid parameters following changes in Positive End Expiratory Pressure

    The percentage of fluid in the lungs (%) and PEEP

    Time frame: During the first 72 hours after Swan-Ganz implantation

  2. Changes in ReDS ICU fluid parameters following raised leg test

    The percentage of fluid in the lungs (%)

    Time frame: During the first 72 hours after Swan-Ganz implantation

  3. Changes in ReDS ICU fluid parameters following changes in body position

    The percentage of fluid in the lungs (%)

    Time frame: During the first 72 hours after Swan-Ganz implantation

  4. Changes in ReDS ICU fluid parameters following changes administration of diuretics and inotropic/inodilators

    The percentage of fluid in the lungs (%)

    Time frame: During the first 72 hours after Swan-Ganz implantation

  5. Correlation between ReDS v2.7 fluid parameters and body weight

    The percentage of fluid in the lungs (%)

    Time frame: 3 months

  6. Correlation between ReDS v2.7 fluid parameters and dyspnea symptom evaluated by NYHA class.

    The percentage of fluid in the lungs (%)

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Sattar Y, Suleiman A, Mir T, et al. TREND OF HEART FAILURE READMISSION PREVENTION IN REMOTE DIELECTRIC SENSING (REDS) MONITORING- A META-ANALYSIS. J Am Coll Cardiol. 2021 May, 77 (18_Supplement_1) 808.
  • Abraham WT, Bensimhon D, Pinney SP, Feitell SC, Peacock WF, Amir O, Burkhoff D. Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial. ESC Heart Fail. 2021 Oct;8(5):3472-3482. doi: 10.1002/ehf2.13550. Epub 2021 Aug 13. PubMed 34390219 ↗
  • Amir O, Azzam ZS, Gaspar T, Faranesh-Abboud S, Andria N, Burkhoff D, Abbo A, Abraham WT. Validation of remote dielectric sensing (ReDS) technology for quantification of lung fluid status: Comparison to high resolution chest computed tomography in patients with and without acute heart failure. Int J Cardiol. 2016 Oct 15;221:841-6. doi: 10.1016/j.ijcard.2016.06.323. Epub 2016 Jul 1. PubMed 27434357 ↗
  • Uriel N, Sayer G, Imamura T, Rodgers D, Kim G, Raikhelkar J, Sarswat N, Kalantari S, Chung B, Nguyen A, Burkhoff D, Abbo A. Relationship Between Noninvasive Assessment of Lung Fluid Volume and Invasively Measured Cardiac Hemodynamics. J Am Heart Assoc. 2018 Nov 20;7(22):e009175. doi: 10.1161/JAHA.118.009175. PubMed 30571493 ↗
  • Lala A, Barghash MH, Giustino G, Alvarez-Garcia J, Konje S, Parikh A, Ullman J, Keith B, Donehey J, Mitter SS, Trivieri MG, Contreras JP, Burkhoff D, Moss N, Mancini DM, Pinney SP. Early use of remote dielectric sensing after hospitalization to reduce heart failure readmissions. ESC Heart Fail. 2021 Apr;8(2):1047-1054. doi: 10.1002/ehf2.13026. Epub 2020 Dec 18. PubMed 33336881 ↗
  • Amir O, Rappaport D, Zafrir B, Abraham WT. A novel approach to monitoring pulmonary congestion in heart failure: initial animal and clinical experiences using remote dielectric sensing technology. Congest Heart Fail. 2013 May-Jun;19(3):149-55. doi: 10.1111/chf.12021. Epub 2013 Jan 25. PubMed 23350643 ↗
  • Bensimhon D, Alali SA, Curran L, Gelbart E, Garman DWV, Taylor R, Chase P, Peacock WF. The use of the reds noninvasive lung fluid monitoring system to assess readiness for discharge in patients hospitalized with acute heart failure: A pilot study. Heart Lung. 2021 Jan-Feb;50(1):59-64. doi: 10.1016/j.hrtlng.2020.07.003. Epub 2020 Jul 20. PubMed 32703623 ↗
  • Imamura T, Hori M, Koi T, Fukui T, Oshima A, Fujioka H, Ueno Y, Onoda H, Tanaka S, Fukuda N, Ueno H, Kinugawa K. Relationship Between Body Posture and Lung Fluid Volume Assessed Using a Novel Noninvasive Remote Dielectric Sensing System. Circ Rep. 2021 Dec 3;4(1):25-28. doi: 10.1253/circrep.CR-21-0130. eCollection 2022 Jan 7. PubMed 35083385 ↗
  • Amir O, Ben-Gal T, Weinstein JM, Schliamser J, Burkhoff D, Abbo A, Abraham WT. Evaluation of remote dielectric sensing (ReDS) technology-guided therapy for decreasing heart failure re-hospitalizations. Int J Cardiol. 2017 Aug 1;240:279-284. doi: 10.1016/j.ijcard.2017.02.120. Epub 2017 Mar 3. PubMed 28341372 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data is planned to be available upon reasonable request via the Principal Investigator pending final, complete publication of the study.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Access and final IPD criteria is pending final, complete publication of the study.

Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA)

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Feb 2024, 19 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 19 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
Jun 6, 2022
StartActual
Jun 13, 2022
Primary completionEst.
Feb 1, 2024
CompletionEst.
Feb 1, 2024
Last update
Jun 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05405504
Lead sponsor
Christian Hassager
Responsible party
Christian Hassager (MD, DMSc, Professor in Cardiology, Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Jun 6, 2022
Start date
Jun 13, 2022
Primary completion
Feb 1, 2024 (estimated)
Completion
Feb 1, 2024 (estimated)
Last update
Jun 14, 2022

Study contacts

Frederik T Sondergaard, MS
Contact
Frederik.tilma.soendergaard@regionh.dk
+4560633626
Rasmus P Beeske, MD
Contact
Rasmus.paulin.beske@regionh.dk
+4530118033
Christian Hassager, MD, DMSc, Professor
principal investigator · Rigshospitalet, Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion